Breakthroughs in the development of highly accurate fluid and neuroimaging biomarkers
have catalysed the conceptual transformation of Alzheimer disease (AD) from the traditional …

The use of biomarkers as early warning systems in the evaluation of disease risk has
increased markedly in the last decade. Biomarkers are indicators of typical biological …

Dementia is a leading cause of disability and death worldwide. At present there is no
disease modifying treatment for any of the most common types of dementia such as …

A sensitive and accurate imaging technique capable of tracking the disease progression of
Alzheimer's Disease (AD) driven amnestic dementia would be beneficial. A currently …

Across neurodegenerative diseases, common mechanisms may reveal novel therapeutic
targets based on neuronal protection, repair, or regeneration, independent of etiology or site …

Neurodegenerative diseases of the brain pose a major and increasing global health
challenge, with only limited progress made in developing effective therapies over the last …

Alzheimer's Disease is a complex, multifactorial, and comorbid condition. The asymptomatic
behavior in the early stages makes the identification of the disease onset particularly …

Frontotemporal dementia encompasses a group of clinical syndromes defined
pathologically by degeneration of the frontal and temporal lobes. Historically, these …

Neurodegenerative disorders are characterised by progressive neuron loss in specific brain
areas. The most common are Alzheimer's disease and Parkinson's disease; in both cases …

This article describes commonly used experimental and clinical biomarkers of neuronal
injury and neurodegeneration for the evaluation of neuropathology and monitoring of …